Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.
复制标题
DOI：
10.3390/pharmaceutics13081183
复制
发表时间：
2021-07-31
期刊：
影响因子：
5.4
通讯作者：
Yang CH
中科院分区：
文献类型：
--
作者：
Satapathy MK;Yen TL;Jan JS;Tang RD;Wang JY;Taliyan R;Yang CH
血脑屏障（BBB）在保护和维持大脑内稳态中起着至关重要的作用。通过这种方式，它是一个有趣的靶点，作为各种类型药物递送的界面，特别是在治疗几种神经病理疾病的背景下，治疗药物不能穿过血脑屏障。药物毒性和靶标特异性是当前神经疗法的一些局限性。近年来，纳米药物递送技术的进步使得含有活性治疗药物的载体系统能够靶向与中枢神经系统（CNS）疾病密切相关的信号通路和病理生理，如阿尔茨海默病（AD）、帕金森病（PD）、亨廷顿病（HD）、多发性硬化症（MS）、脑肿瘤、癫痫、缺血性中风和神经变性。目前，在纳米制剂中，固体脂质纳米颗粒（SLNs）作为一种可能的药物载体系统已经出现，它可以将活性药物（载药SLNs）通过脑血脑屏障传递到大脑的靶部位，提供了一种新的药物传递途径，具有可控制的药物传递、更长的循环时间、靶向特异性和更高的疗效，更重要的是，以仿生方式降低毒性。本文重点介绍了sln的合成和应用，作为一种新的无毒配方策略，通过血脑屏障携带中枢神经系统药物，以提高治疗药物在未来临床治疗主要神经系统疾病中的使用。
The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
登录
查看更多内容
DOI：
10.1016/j.nurt.2009.01.018
发表时间：
2009-04
期刊：
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
影响因子：
--
作者：
Bennewitz MF;Saltzman WM
通讯作者：
Saltzman WM
影响因子：
9.3
作者：
Bargoni, A;Cavalli, R;Gasco, MR
通讯作者：
Gasco, MR
DOI：
10.1602/neurorx.2.4.554
发表时间：
2005-10-01
期刊：
NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics
影响因子：
--
作者：
Alavijeh, Mohammad S;Chishty, Mansoor;Palmer, Alan M
通讯作者：
Palmer, Alan M
DOI：
10.1016/s1773-2247(10)50028-5
发表时间：
2010-05-01
影响因子：
5
作者：
Bianco, M. A.;Gallarate, M.;Battaglia, L.
通讯作者：
Battaglia, L.
影响因子：
13.5
作者：
Banks, William A.;Owen, Joshua B.;Erickson, Michelle A.
通讯作者：
Erickson, Michelle A.